18 recruiting, 12 completed, 5 terminated, 2 not yet recruiting. 22 Phase 2, 11 Phase 3, 10 Phase 1, 2 Phase 4, 1 Not applicable.
Follow Rescue Medication: new trials by email Literature Review of Rescue Medication trials Research Report on Rescue Medication
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007) MK-6916, Hydrocodone/acetaminophen (HB/APAP), MK-6916 Placebo - Pain Management | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 380 | 2026-11-23 | 2026-10-07 |
| A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005) MK-4082, Diltiazem, Rescue medication - Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 28 | 2026-07-20 | 2026-08-05 |
| A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) I-DXd, Rescue Medication - Oesophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 60 | 2026-03-27 | 2026-10-02 |
| KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) MK-3120, EV, Pembrolizumab - Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 55 | 2026-02-09 | 2026-10-02 |
| KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) MK-1084, Pembrolizumab, Cetuximab - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2025-12-19 | 2026-09-02 |
| Study Comparing Atomizerd Midazolam & Fentanyl and Dexmedomidine for Procedural Sedation in Adult and Pediatric Patient (2 to 60 Years Old) atomizer, rescue medication, Midazolam - Sedation, Analgesia Assessment | Not applicable | Not yet recruiting | Oman Medical Speciality Board | 128 | 2025-09-01 | 2025-09-10 |
| Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Pembrolizumab, I-DXd, Leucovorin - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 298 | 2025-07-30 | 2026-10-27 |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel - Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1000 | 2025-07-21 | 2026-10-23 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Breast Neoplasms, Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 2400 | 2025-06-30 | 2026-10-13 |
| Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) R-DXD, I-DXD, Docetaxel - Lung Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 144 | 2025-05-28 | 2026-10-07 |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Ifinatamab deruxtecan, Docetaxel, Prednisone - Prostate Cancer, Prostatic Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1440 | 2025-05-13 | 2026-10-30 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). Raludotatug Deruxtecan, Carboplatin, Paclitaxel - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 605 | 2025-04-15 | 2026-10-30 |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) Zilovertamab vedotin, Rituximab, Cyclophosphamide - Lymphoma, Large B-Cell, Diffuse | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 594 | 2025-04-11 | 2026-10-08 |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1000 | 2025-03-16 | 2026-10-13 |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) Zilovertamab vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1046 | 2025-01-27 | 2026-10-21 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 32 | 2024-12-20 | 2026-10-15 |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin - Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-06-20 | 2026-10-29 |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) Sacituzumab tirumotecan, Pembrolizumab, Cisplatin - Non Small Cell Lung Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 780 | 2024-04-03 | 2026-10-15 |
| Preemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft Ibuprofen 600 mg, Placebo, Acetaminophen - Pain, Post Operative, Quality of Life | Phase 4 | Recruiting | Marquette University | 50 | 2023-10-19 | 2024-09-27 |
Showing 20 of 39. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (5) · Migraine Disorders (3) · Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Asthma (2) · Bipolar Disorder (2) · Breast Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Lung Neoplasms (2) · Lymphoma, Large B-Cell, Diffuse (2) · Triple Negative Breast Neoplasms (2) · Vomiting (2) · Agnosia (1) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1)
Merck Sharp & Dohme LLC (25) · GlaxoSmithKline (4) · Allergan (2) · Organon and Co (2) · ALK-Abelló A/S (1) · AstraZeneca (1) · Gachon University Gil Medical Center (1) · Hospital de Clinicas de Porto Alegre (1) · Marquette University (1) · Oman Medical Speciality Board (1)
United States (21) · South Korea (15) · Spain (15) · Chile (13) · Italy (12) · United Kingdom (12) · China (11) · Germany (11) · Israel (11) · Taiwan (11) · Turkey (Türkiye) (11) · Australia (10) · Brazil (10) · Canada (10) · France (10)
Andrea Ludwig-Sengpiel, Dr. (1) · Anne-Marie Kirsten, Dr. (1) · Anneliese Linnhoff, Dr. med. (1) · Christine Grigat, Dr. (1) · Dirk Skowasch, Prof. (1) · Jutta Beier, Dr. med. (1) · Margret Jandl, Dr. (1) · Oliver Kornmann, Dr. (1) · Rainard Fuhr, Dr. med. (1) · Sang Min Lee, MD, PhD (1) · Tanya Kralimarkova, Dr. (1) · Ulrike Westerhausen, Dr. (1)
PMID 26598478, PMID 19001265, PMID 21054362, PMID 22464647, PMID 22702508, PMID 23374268, PMID 24035151, PMID 25695403, PMID 26706294, PMID 26755098, PMID 27461426, PMID 30125349, PMID 30777086, PMID 34088322, PMID 39982105, PMID 42535874, PMID 42872715
2025 (3), 2023 (2), 2005 (1), 2008 (1), 2014 (1), 2016 (1), 2017 (1)